Advertisement

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Welcome and Introduction to Vi3C

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Advertisement

Advertisement




Apr
08
Today In Oncology
Analysis Shows Nearly 7 Percent of Global Clinical Trials Are Impacted by Middle East Conflict
Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer
Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer
Ablative Radiotherapy May Improves Outcomes for Patients With Large Intrahepatic Cholangiocarcinoma
Setidegrasib in Advanced NSCLC and Pancreatic Cancer Harboring the KRAS p.G12D Variant
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo